欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (10): 1087-1090.

• 综述 • 上一篇    下一篇

细胞膜糖蛋白P170 抑制剂的研究进展

张育   

  1. 扬州大学医学院内科学教研室, 扬州市血液学研究所, 扬州225001, 江苏
  • 收稿日期:2004-07-27 修回日期:2004-09-07 出版日期:2004-10-26 发布日期:2020-11-23
  • 通讯作者: 张育, 男, 副教授, 副主任医师, 研究方向:血液肿瘤的诊断和治疗。Tel:0514-7190350 E-mail:yzzy1018 @hotmail.com

Progress in the research of P-gp inhibitors

ZHANG Yu   

  1. Department of Internal Medicine, School of Medical, Yangzhou University, Yangzhou 225001, Jiangsu, China
  • Received:2004-07-27 Revised:2004-09-07 Online:2004-10-26 Published:2020-11-23

摘要: 多药耐药性的发生是肿瘤治疗失败的原因之一, 而肿瘤细胞多药耐药基因1(MDR1) 编码的细胞膜糖蛋白P170 表达的增加是最常见的发生机制。近年来针对细胞膜糖蛋白P170 抑制剂的研究有了很大进展, 本文就目前细胞膜糖蛋白P170 抑制剂的研究状况进行综述。

关键词: 肿瘤, 多药耐药, P-糖蛋白, 基因表型

Abstract: Multidrug resistance (MDR) is one of the major obstacles to cancer chemotherapy. It is now well established that MDR phenotype is strongly correlated with the over-expression of P-glycoprotein (P-gp), a membrane glycoprotein encoded by MDR1 gene. There is very great progress in the research of the P-gp inhibitors in recent years. This article describes the current research state of the P-gp inhibitors.

Key words: tumor, multidrug resistance, P-glycoprotein inhibitor, phenotype

中图分类号: